Biosimilars: Much Ado About Nothing, Part 1

By Brittany | March 23, 2012 | Category: Pharmacotherapy
Biosimilars: Much Ado About Nothing, Part 1
By Ralph Tarantino, PhD
Pharmaceutical Consultant and Principal, SteriTech Solutions, LLC
Middletown, NJ

The eagerly awaited draft guidance on biosimilars* was finally issued by the FDA on February 9, 2012. It was drafted in the spirit of enlightened health care reform, with a view towards fiscal responsibility and. . . to annoy the nemesis of all that is good in health care, “Greedy Big Pharma.”

[More]


Month List

RecentComments

Comment RSS